SCHEMBL17834934

SCHEMBL17834934

CCCc1ccc(-c2ccc(-c3cnc(-c4ccc(C[C@H](NC(=O)c5ccc(C(F)(F)F)cc5)C(=O)N5CC(C(=O)O)C5)cc4)nc3)c(F)c2)cc1

nearest known ligand 0.40

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ KIFC1 Q9BW19 6/20 0.40
▸ ALOX5AP P20292 5/20 0.40
▸ FEN1 P39748 5/20 0.40
▸ S1PR5 Q9H228 2/20 0.38
▸ CTSL P07711 1/20 0.38
▸ PPARD Q03181 1/20 0.36
▸ GPR132 Q9UNW8 1/20 0.36
▸ PYGL P06737 1/20 0.36
▸ MTTP P55157 1/20 0.35
▸ S1PR4 O95977 1/20 0.35
▸ S1PR1 P21453 1/20 0.35
▸ S1PR3 Q99500 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17834937 0.94 KIFC1 (0.37) KIFC1ALOX5APFEN1S1PR5PYGL
SCHEMBL17834794 0.93 S1PR1 (0.39) KIFC1ALOX5APFEN1S1PR5PYGL
SCHEMBL17995149 0.93 S1PR1 (0.40) S1PR5PYGLS1PR4S1PR1S1PR3
SCHEMBL17995193 0.91 PYGL (0.37) ALOX5APFEN1S1PR5CTSLPYGL
SCHEMBL17995153 0.91 CCR1 (0.39) S1PR5PYGLS1PR4S1PR1S1PR3
SCHEMBL17834792 0.90 PSMB5 (0.35) S1PR5PYGLS1PR4S1PR1S1PR3
SCHEMBL17995228 0.90 KDM1A (0.40) S1PR5PYGLS1PR4S1PR1S1PR3
SCHEMBL17834662 0.86 KIFC1 (0.37) KIFC1S1PR5PYGLS1PR4S1PR1
SCHEMBL19485639 0.85 ALOX5AP (0.39) KIFC1ALOX5APFEN1S1PR5PYGL
SCHEMBL17834425 0.85 KIFC1 (0.38) KIFC1ALOX5APFEN1S1PR5PYGL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3230276-B1 GLP-1 RECEPTOR MODULATORS CELGENE INT II SARL (CH) 2020-09-02 — — EP disclosed
US-10034886-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2018-07-31 — — US disclosed
US-20180021346-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2018-01-25 — — US disclosed
US-9795613-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2017-10-24 — — US disclosed
WO-2016094729-A1 GLP-1 RECEPTOR MODULATORS CELGENE INTERNATIONAL II SARL (CH) 2016-06-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180021346-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R KIFC1 4738/4885ALOX5AP 3115/4885FEN1 3722/4885
US-10034886-B2 GLP-1 receptor modulators GLP1R, GIPR, GCGR KIFC1 4749/4885ALOX5AP 3438/4885FEN1 3634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback